​

Viking Therapeutics (VKTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

VKTX Stock Forecast

Viking Therapeutics (VKTX) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $103.50, with a high of $105.00 and a low of $102.00. This represents a 188.06% increase from the last price of $35.93.

$15 $33 $51 $69 $87 $105 High: $105 Avg: $103.5 Low: $102 Last Closed Price: $35.93

VKTX Stock Rating

Viking Therapeutics stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 1 Strong Buy (4.55%), 20 Buy (90.91%), 1 Hold (4.55%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 1 20 1 Strong Sell Sell Hold Buy Strong Buy

VKTX Price Target Upside V Benchmarks

TypeNameUpside
StockViking Therapeutics188.06%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts226
Avg Price Target$103.50$103.50$96.00
Last Closing Price$35.93$35.93$35.93
Upside/Downside188.06%188.06%167.19%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 256101--17
Sep, 256102--18
Aug, 257102--19
Jul, 257102--19
Jun, 257102--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 23, 2025Morgan Stanley$102.00$31.42224.63%183.89%
Oct 23, 2025Cantor Fitzgerald$105.00$31.42234.18%192.23%
Apr 28, 2025Joon LeeTruist Financial$75.00$25.94189.13%108.74%
Dec 02, 2024Biren AminPiper Sandler$74.00$52.9439.78%105.96%
Nov 04, 2024Yale JenLaidlaw$110.00$63.1474.22%206.15%
Nov 04, 2024Roger SongJefferies$110.00$63.1474.22%206.15%
Jun 27, 2024Michael UlzMorgan Stanley$105.00$47.39121.57%192.23%
Jun 25, 2024Joseph PantginisH.C. Wainwright$90.00$52.1272.68%150.49%
May 16, 2024Steve SeedhouseRaymond James$116.00$69.0667.97%222.85%
May 16, 2024Joon LeeTruist Financial$120.00$69.5372.59%233.98%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2025Morgan StanleyOverweightOverweighthold
Sep 22, 2025BTIGBuyBuyhold
Jun 25, 2025BTIGBuyBuyhold
Apr 28, 2025Cantor FitzgeraldOverweightinitialise
Apr 14, 2025BTIGBuyBuyhold
Mar 12, 2025Morgan StanleyOverweightOverweighthold
Dec 02, 2024Piper SandlerOverweightinitialise
Nov 04, 2024LaidlawBuyBuyhold
Nov 04, 2024JefferiesBuyBuyhold
Oct 17, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.50$-0.91$-1.01----
Avg Forecast$-0.55$-0.92$-0.95$-1.49$-1.83$-1.80$-0.34
High Forecast$-0.55$-0.88$-0.78$-1.21$-0.32$2.05$-0.34
Low Forecast$-0.55$-0.94$-1.28$-2.19$-2.74$-3.74$-0.34
Surprise %-9.09%-1.09%6.32%----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-------
Avg Forecast$6.19M--$2.50M$35.54M$124.95M$430.93M
High Forecast$7.43M--$2.50M$35.54M$124.95M$430.93M
Low Forecast$4.95M--$2.50M$35.54M$124.95M$430.93M
Surprise %-------

Net Income Forecast

$-400M $-280M $-160M $-40M $80M $200M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-36.05M$-85.89M$-109.96M----
Avg Forecast$-29.66M$-85.89M$-99.15M$-167.28M$-209.46M$-224.26M$-32.35M
High Forecast$-23.73M$-83.39M$-73.18M$-114.61M$-30.59M$193.69M$-32.35M
Low Forecast$-35.59M$-89.01M$-120.42M$-206.30M$-258.13M$-353.26M$-32.35M
Surprise %21.54%-10.90%----

VKTX Forecast FAQ

Is Viking Therapeutics stock a buy?

Viking Therapeutics stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 20 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Viking Therapeutics is a favorable investment for most analysts.

What is Viking Therapeutics's price target?

Viking Therapeutics's price target, set by 22 Wall Street analysts, averages $103.5 over the next 12 months. The price target range spans from $102 at the low end to $105 at the high end, suggesting a potential 188.06% change from the previous closing price of $35.93.

How does Viking Therapeutics stock forecast compare to its benchmarks?

Viking Therapeutics's stock forecast shows a 188.06% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Viking Therapeutics over the past three months?

  • October 2025: 35.29% Strong Buy, 58.82% Buy, 5.88% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 36.84% Strong Buy, 52.63% Buy, 10.53% Hold, 0% Sell, 0% Strong Sell.

What is Viking Therapeutics’s EPS forecast?

Viking Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.49, marking a 47.52% increase from the reported $-1.01 in 2024. Estimates for the following years are $-1.83 in 2026, $-1.8 in 2027, and $-0.34 in 2028.

What is Viking Therapeutics’s revenue forecast?

Viking Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $2.5M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $35.54M, followed by $124.95M for 2027, and $430.93M for 2028.

What is Viking Therapeutics’s net income forecast?

Viking Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-167M, representing an 52.12% increase from the reported $-110M in 2024. Projections indicate $-209M in 2026, $-224M in 2027, and $-32.348M in 2028.